<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04839055</url>
  </required_header>
  <id_info>
    <org_study_id>JiangnanU RWang-1</org_study_id>
    <nct_id>NCT04839055</nct_id>
  </id_info>
  <brief_title>The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC</brief_title>
  <acronym>CoA-CRPC</acronym>
  <official_title>The Purpose of This Study is to Compare the Therapy Effects and Clinical Safety of a Regulatory Metabolic Compound, Coenzyme A (CoA) With a Marketed Drug, Abiraterone, in Chinese Patients With Castration-resistant Prostate Cancer (CRPC) .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangnan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affiliated Hospital of Jiangnan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangnan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the therapy effects and clinical safety of a&#xD;
      regulatory metabolic compound, coenzyme A (CoA) with a marketed drug, abiraterone, in Chinese&#xD;
      patients with castration-resistant prostate cancer (CRPC) .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate Cancer (PCa) has developed into the second most common cancer in men. In The United&#xD;
      States, PCa has the highest morbidity in man. In China, the incidence rate is lower than in&#xD;
      Europe and the US, but it is growing faster and faster. Androgen deprivation therapy (ADT)&#xD;
      has been the most commonly used treatment for men with advanced prostate cancer for hundreds&#xD;
      of years, effective in more than 85 percent of cases, but usually after 20 months or so, half&#xD;
      of patients will inevitably develop castration-resistant prostate cancer (CRPC), which will&#xD;
      become resistant to ADT, and patients will relapse. There are several treatments that are&#xD;
      trying to address this problem. Such as the chemotherapy docetaxel, cabataxel, and the&#xD;
      radioactive drug radium 223 dichloride; PARP inhibitor olaparib, but the efficacy is limited.&#xD;
&#xD;
      For finding some new pathways and targets to treat CRPC, a model of PCa persister cell was&#xD;
      first been established at a cellular level in this study. In light of the new target, we&#xD;
      first find a being used clinically drug, Coenzyme A (CoA), through prescription sieve to&#xD;
      treat enzalutamide or abiraterone drug-fast CRPC patients. CoA functions as an acyl group&#xD;
      carrier and assists in transferring fatty acids from the cytoplasm to mitochondria. It is&#xD;
      also involved in the oxidation and catabolism of fatty acids. There is an efficient drug&#xD;
      action at a cellular level and in animals, and we look forward to it at clinical utility.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total prostate specific antigen (TPSA) level</measure>
    <time_frame>2 weeks</time_frame>
    <description>The primary efficacy variable from 12.82 ng/mL to 13.01 ng/mL in serum TPSA level and 2 weeks of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Castration-resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental: Coenzyme A 200U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coenzyme A 200U per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Abiraterone without coenzyme A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coenzyme A Combined With Abiraterone</intervention_name>
    <description>Abiraterone 4 pieces per day. Coenzyme A 200U</description>
    <arm_group_label>Experimental: Coenzyme A 200U</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>Abiraterone</description>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - 18-100 years of age combined use with abiraterone or enzalutamide CRPC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - pregnancy acute liver disease or hepatic dysfunction, as determined by levels of alanine&#xD;
        aminotransferase (ALT) or aspartate aminotransferase levels (AST) more than 2-fold the&#xD;
        upper normal limit nephrotic syndrome or serum creatinine (Cr) â‰¥2-fold the upper normal&#xD;
        limit and creatine phosphokinase (CK) more than 3-fold the upper normal limit primary&#xD;
        hypothyroidism psychiatric patients poorly controlled hypertension, as indicated by a&#xD;
        Systolic Blood Pressure &gt;180 mmHg or Diastolic Blood Pressure &gt;110 mmHg using contraceptive&#xD;
        agent using immunosuppressive drugs, prohibited medication or other non-PCa drugs long-term&#xD;
        using CoA drug&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YongQuan Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jiangnan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YongQuan Chen, MD</last_name>
    <phone>051013812517168</phone>
    <email>yqchen@jiangnan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rong Wang, EM</last_name>
    <phone>051018652457101</phone>
    <email>840174458@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jiangnan University</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YongQuan Chen, MD</last_name>
      <phone>051013812517168</phone>
      <email>yqchen@jiangnan.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>rong wang, EM</last_name>
      <phone>051018652457101</phone>
      <email>W0826R@outlook.com</email>
    </contact_backup>
    <investigator>
      <last_name>YongQuan Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

